Name of this trial: OptimUM-10
What type of cancer is this for? Uveal Melanoma
Who is this trial for? Subjects with Primary Non-metastatic Uveal Melanoma
What biomarkers are involved? Monosomy 3
What is the National Clinical Trial #? NCT07015190; https://clinicaltrials.gov/study/NCT07015190
Brief summary of this trial: A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects with Primary Non-metastatic Uveal Melanoma
Need to know: Must be at high risk of metastasis defined by at least one of the following: Monosomy 3, Class 2 GEP, Stage 3 by AJCC. Must not have had previous treatment for uveal melanoma or have evidence of metastatic uveal melanoma.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: IDE 196-001
What type of cancer is this for? Metastatic Uveal Melanoma
Who is this trial for? Patients with confirmed metastatic disease which progresses on or after most recent treatment, or for patients with no treatment in the metastatic setting.
What biomarkers are involved? GNAQ/11
What is the National Clinical Trial #? NCT03947385
Brief summary of this trial: Patients eligible for this trial will receive investigational oral drug IDE196 plus Crizotinib (oral drug), both drugs will be taken twice daily.
Need to know: All potentially eligible patients will have tumor and blood samples sent to central laboratory for confirmation of GNAQ/11. First couple weeks on trial will include long days in clinic and eye exams will be required every 4 weeks.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]